News

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.

12/20/2024

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation.

12/19/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Aadi Bioscience, Inc. (AADI) a buy, sell, or hold?

Aadi Bioscience, Inc. (AADI) can sell. Click on Rating Page for detail.

What is Aadi Bioscience, Inc.'s stock price?

The price of Aadi Bioscience, Inc. (AADI) is 3.39 and it was updated on 2024-12-21 07:00:45.

Is Aadi Bioscience, Inc. (AADI) overvalued or undervalued?

Currently Aadi Bioscience, Inc. (AADI) is in undervalued.

News

From:

To:

News
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago. Wed, Nov. 06, 2024
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth Aadi continues to focus on FYARRO commercial business and comprehensive strategic review to maximize shareholder value LOS ANGELES , Nov. 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand and a nearly 90 percent reorder rate – all reinforcing the clinical value of FYARRO for patients with advanced malignant PEComa," said Dave Lennon, President and CEO of Aadi Bioscience. Wed, Nov. 06, 2024
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. Wed, Oct. 30, 2024
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026 LOS ANGELES , Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. Tue, Aug. 20, 2024
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants David Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience Inc. Second Quarter 2024 Earnings Call. Sat, Aug. 10, 2024

Transcripts

Transcipts Data
Aadi Bioscience, Inc. (AADI) on Q2 2024 Results - Earnings Call Transcript SA Transcripts Sat, Aug. 10, 2024
Aadi Bioscience, Inc. (AADI) on Q1 2024 Results - Earnings Call Transcript SA Transcripts Wed, May. 08, 2024
Aadi Bioscience, Inc. (AADI) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Wed, Mar. 13, 2024
Aadi Bioscience, Inc. (AADI) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Wed, Nov. 08, 2023
Aadi Bioscience, Inc. (AADI) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Wed, Aug. 09, 2023
Aadi Bioscience, Inc. (AADI) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Wed, May. 10, 2023
Aadi Bioscience, Inc. (AADI) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Tue, Mar. 28, 2023
Aadi Bioscience, Inc. (AADI) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Wed, Nov. 09, 2022
Aadi Bioscience, Inc. (AADI) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Wed, Aug. 10, 2022
Aadi Bioscience, Inc. (AADI) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Thu, May. 12, 2022

SEC Filings

SEC Filings
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 12/20/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 12/20/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/06/2024
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/06/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 10/03/2024
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 10/01/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/30/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/19/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/05/2024
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 09/03/2024
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 08/28/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/22/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/21/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/07/2024
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/07/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 08/05/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/02/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/14/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/12/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/05/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/08/2024
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/08/2024
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 05/03/2024
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 05/01/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 05/01/2024
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 04/26/2024
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 04/26/2024
Aadi Bioscience, Inc. (AADI) - ARS SEC Filings 04/26/2024
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 04/26/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 04/04/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/03/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/13/2024
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/13/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/04/2024
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 02/12/2024
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 02/12/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 02/02/2024
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 01/02/2024
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 12/14/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/07/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/05/2023
Aadi Bioscience, Inc. (AADI) - 8-K/A - Current report SEC Filings 11/08/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/08/2023
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/08/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 11/02/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 10/03/2023
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 10/03/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 10/02/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/06/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/09/2023
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/09/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 08/03/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/06/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/20/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/16/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/06/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/05/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/10/2023
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/10/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 05/05/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 05/03/2023
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 04/28/2023
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 04/28/2023
Aadi Bioscience, Inc. (AADI) - ARS SEC Filings 04/28/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/06/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/05/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/04/2023
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 03/29/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/29/2023
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 03/29/2023
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/29/2023
Aadi Bioscience, Inc. (AADI) - 8-K/A - Current report SEC Filings 03/28/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/28/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/03/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/02/2023
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/14/2023
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/10/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/23/2023
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 01/17/2023
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 01/04/2023
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 12/07/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/28/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/09/2022
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/09/2022
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 11/07/2022
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 11/04/2022
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 11/02/2022
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 11/01/2022
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 10/26/2022
Aadi Bioscience, Inc. (AADI) - D SEC Filings 10/11/2022
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 10/04/2022
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/27/2022
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 09/26/2022
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/26/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/22/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/10/2022
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/10/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/30/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/29/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/17/2022
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/17/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/12/2022
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/12/2022
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 04/26/2022
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 04/26/2022
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/05/2022
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/22/2022
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 03/21/2022
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 03/18/2022
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 03/17/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/17/2022
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 03/17/2022
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/17/2022
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/14/2022
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 02/14/2022
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/11/2022
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/09/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/20/2022
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/19/2022
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 11/29/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/23/2021
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 11/15/2021
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 11/12/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/10/2021
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/10/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/01/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 10/25/2021
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 10/25/2021
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 10/04/2021
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 10/04/2021
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 10/04/2021
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 10/01/2021
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 09/30/2021
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 09/29/2021
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 09/24/2021
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 09/24/2021
Aadi Bioscience, Inc. (AADI) - 8-K/A - Current report SEC Filings 09/24/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/22/2021
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 09/22/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/20/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/13/2021
Aadi Bioscience, Inc. (AADI) - D SEC Filings 09/10/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/10/2021
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 09/10/2021
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 09/08/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 09/07/2021
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 09/07/2021
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 09/03/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 09/03/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 09/02/2021
Aadi Bioscience, Inc. (AADI) - 4/A SEC Filings 08/31/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 08/31/2021
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 08/31/2021
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 08/30/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 08/30/2021
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 08/30/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/27/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 08/23/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/23/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/18/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/11/2021
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/11/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 07/26/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 07/12/2021
Aadi Bioscience, Inc. (AADI) - DEFM14A SEC Filings 07/08/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/02/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/22/2021
Aadi Bioscience, Inc. (AADI) - PREM14A SEC Filings 06/21/2021
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 06/09/2021
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 06/09/2021
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 06/04/2021
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 06/04/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/04/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 05/26/2021
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 05/20/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/20/2021
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 05/17/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/17/2021
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/17/2021
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 04/16/2021
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 04/13/2021
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 04/12/2021
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 04/08/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/02/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 04/01/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/11/2021
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/11/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/05/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 02/16/2021
Aadi Bioscience, Inc. (AADI) - SC 13G/A SEC Filings 02/10/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 02/10/2021
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 02/03/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 02/01/2021
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 01/11/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/05/2021
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 12/11/2020
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/10/2020
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 11/23/2020
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 11/12/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/10/2020
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/10/2020
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 09/25/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/12/2020
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/12/2020
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 08/05/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/04/2020
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/26/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/25/2020
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 06/08/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/28/2020
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 05/15/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/12/2020
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 05/08/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/07/2020
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/07/2020
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 04/27/2020
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 04/27/2020
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 04/22/2020
Aadi Bioscience, Inc. (AADI) - PRE 14A SEC Filings 04/17/2020
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/18/2020
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 03/16/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/16/2020
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/16/2020
Aadi Bioscience, Inc. (AADI) - SC 13G SEC Filings 03/09/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/27/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/08/2020
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/07/2019
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/07/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 11/06/2019
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 10/24/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 10/18/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 10/10/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/08/2019
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/08/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 07/26/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/10/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/08/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/19/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/19/2019
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 06/07/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/16/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 05/16/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/09/2019
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/09/2019
Aadi Bioscience, Inc. (AADI) - DEFA14A SEC Filings 04/30/2019
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 04/30/2019
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 04/29/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/29/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/24/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/15/2019
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 04/11/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 04/10/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/10/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/05/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 04/04/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/02/2019
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 03/28/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/28/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/28/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/18/2019
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 03/07/2019
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/07/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/05/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 02/20/2019
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 02/13/2019
Aadi Bioscience, Inc. (AADI) - 5 SEC Filings 02/13/2019
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 02/11/2019
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 02/08/2019
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 01/11/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 01/10/2019
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/07/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 01/07/2019
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 01/02/2019
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 12/28/2018
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 12/28/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/27/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/20/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/14/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/11/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/06/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 11/30/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 11/16/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 11/14/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/07/2018
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/07/2018
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 10/04/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 09/26/2018
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 09/19/2018
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 09/14/2018
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 09/11/2018
Aadi Bioscience, Inc. (AADI) - POS AM SEC Filings 08/31/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 08/22/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/14/2018
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/14/2018
Aadi Bioscience, Inc. (AADI) - CT ORDER SEC Filings 07/24/2018
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 07/09/2018
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 07/03/2018
Aadi Bioscience, Inc. (AADI) - SC 13D/A SEC Filings 07/02/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 07/02/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/29/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/27/2018
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 06/26/2018
Aadi Bioscience, Inc. (AADI) - CERT SEC Filings 06/25/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/25/2018
Aadi Bioscience, Inc. (AADI) - 8-A12B SEC Filings 06/25/2018
Aadi Bioscience, Inc. (AADI) - 424B5 SEC Filings 06/25/2018
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 06/25/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/22/2018
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 06/22/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 06/22/2018
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 06/22/2018
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 06/11/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/29/2018
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 05/25/2018
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 05/21/2018
Aadi Bioscience, Inc. (AADI) - DEF 14A SEC Filings 05/15/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/15/2018
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 04/25/2018
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 04/12/2018
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 04/09/2018
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 04/06/2018
Aadi Bioscience, Inc. (AADI) - S-3/A SEC Filings 04/06/2018
Aadi Bioscience, Inc. (AADI) - 10-K/A - Current report SEC Filings 04/06/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 04/02/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/23/2018
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/21/2018
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/15/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/13/2018
Aadi Bioscience, Inc. (AADI) - S-3 SEC Filings 02/21/2018
Aadi Bioscience, Inc. (AADI) - 5 SEC Filings 02/14/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 01/08/2018
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 12/18/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 12/18/2017
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 12/18/2017
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 12/06/2017
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 11/16/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 11/14/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 11/14/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 11/13/2017
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/13/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 10/10/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 10/10/2017
Aadi Bioscience, Inc. (AADI) - S-8 SEC Filings 08/18/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 08/15/2017
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/10/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 08/08/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 08/08/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 07/31/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 07/31/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 06/29/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 06/29/2017
Aadi Bioscience, Inc. (AADI) - EFFECT SEC Filings 06/26/2017
Aadi Bioscience, Inc. (AADI) - 424B3 SEC Filings 06/26/2017
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 06/21/2017
Aadi Bioscience, Inc. (AADI) - S-1/A SEC Filings 06/09/2017
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 06/09/2017
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 06/08/2017
Aadi Bioscience, Inc. (AADI) - S-1/A SEC Filings 05/22/2017
Aadi Bioscience, Inc. (AADI) - CORRESP SEC Filings 05/22/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 05/16/2017
Aadi Bioscience, Inc. (AADI) - UPLOAD SEC Filings 05/15/2017
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2017
Aadi Bioscience, Inc. (AADI) - S-1 SEC Filings 04/14/2017
Aadi Bioscience, Inc. (AADI) - D SEC Filings 03/30/2017
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 03/28/2017
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 03/27/2017
Aadi Bioscience, Inc. (AADI) - DEFM14C SEC Filings 03/27/2017
Aadi Bioscience, Inc. (AADI) - PREM14C SEC Filings 03/17/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/17/2017
Aadi Bioscience, Inc. (AADI) - 4 SEC Filings 03/17/2017
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 03/17/2017
Aadi Bioscience, Inc. (AADI) - 8-K - Current report SEC Filings 03/13/2017
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/07/2017
Aadi Bioscience, Inc. (AADI) - SC 14F1 SEC Filings 02/24/2017
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/14/2016
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/15/2016
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/16/2016
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/30/2016
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/13/2015
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/13/2015
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/13/2015
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 02/27/2015
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/14/2014
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/14/2014
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2014
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/31/2014
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/14/2013
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/14/2013
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2013
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/28/2013
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/14/2012
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/14/2012
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2012
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/30/2012
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/14/2011
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/15/2011
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/16/2011
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/31/2011
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/15/2010
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/13/2010
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/17/2010
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/31/2010
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/16/2009
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 08/14/2009
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 05/15/2009
Aadi Bioscience, Inc. (AADI) - 10-K - Current report SEC Filings 03/31/2009
Aadi Bioscience, Inc. (AADI) - 10-Q - Quarterly Report SEC Filings 11/12/2008
Aadi Bioscience, Inc. (AADI) - 10QSB SEC Filings 08/11/2008
Aadi Bioscience, Inc. (AADI) - 10QSB SEC Filings 05/15/2008
Aadi Bioscience, Inc. (AADI) - SC 13D SEC Filings 04/04/2008
Aadi Bioscience, Inc. (AADI) - 3 SEC Filings 04/04/2008
Aadi Bioscience, Inc. (AADI) - 10SB12G SEC Filings 02/01/2008

Press Releases

StockPrice Release
Aadi bioscience transforms with in-licensing of novel adc portfolio, $100 million sale of fyarro® and $100 million pipe financing 12/19/2024
Aadi bioscience announces financial results for the third quarter 2024 and provides corporate update 11/06/2024
Aadi bioscience to report third quarter 2024 results and corporate update 10/30/2024
Aadi bioscience provides precision1 trial and corporate updates 08/20/2024
Aadi bioscience announces financial results for the second quarter 2024 and provides corporate update 08/07/2024
Aadi bioscience to report second quarter 2024 results and corporate update 07/31/2024
Aadi bioscience to participate in the jefferies healthcare conference 05/29/2024
Aadi bioscience presents new nonclinical data demonstrating preferential tumor uptake of nab-sirolimus at the american society of clinical oncology (asco) annual meeting 05/23/2024
Aadi bioscience announces financial results for the first quarter 2024 and provides corporate update 05/08/2024
Aadi bioscience to report first quarter 2024 results and corporate update 05/01/2024
Aadi bioscience to present new non-clinical data highlighting combinability of nab-sirolimus at the american association for cancer research (aacr) annual meeting 04/09/2024
Aadi bioscience presents new subgroup analysis of patients with advanced malignant pecoma of gynecologic origin treated with nab-sirolimus at society of gynecologic oncology (sgo) 03/17/2024
Aadi bioscience announces financial results for the fourth quarter and full-year 2023 and provides corporate update 03/13/2024
Aadi bioscience to report fourth quarter and full-year 2023 results and corporate update 03/06/2024
Aadi bioscience to present multiple posters at the american association for cancer research (aacr) annual meeting 2024 03/05/2024
Aadi bioscience announces publication of long-term efficacy and safety data further supporting fyarro® for the treatment of malignant pecoma 03/01/2024
Aadi bioscience to present at the td cowen 44th annual healthcare conference 02/26/2024
Aadi bioscience announces poster presentations at the 2024 american society of clinical oncology (asco) genitourinary (gu) cancers symposium 01/26/2024
Aadi bioscience announces poster presentations at the 2024 american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium 01/19/2024
Aadi bioscience reports interim results from precision1 trial of nab-sirolimus demonstrating anti-tumor activity in solid tumors with tsc1 or tsc2 inactivating alterations 12/14/2023
Aadi bioscience reports financial results for the third quarter 2023 and provides corporate update 11/08/2023
Aadi bioscience to participate in jefferies london healthcare conference 11/06/2023
Aadi bioscience announces poster presentations on nab-sirolimus at the international gynecologic cancer society (igcs) 2023 annual global meeting 10/19/2023
Aadi bioscience announces poster presentations at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics 10/12/2023
Aadi bioscience announces poster presentations at the north american neuroendocrine tumor society (nanets) 2023 multidisciplinary net medical symposium 10/05/2023
Aadi bioscience grants new ceo dave lennon, ph.d. inducement award under nasdaq listing rule 5635 (c)(4) 10/03/2023
Aadi bioscience appoints dave lennon, ph.d. as president and chief executive officer 10/02/2023
Aadi bioscience announces poster presentations at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics 09/20/2023
Aadi bioscience to participate at upcoming investor conferences 09/05/2023
Aadi bioscience announces financial results for the second quarter 2023 and provides corporate update 08/09/2023
Aadi bioscience to report second quarter 2023 results and operational update 08/02/2023
Aadi bioscience announces presentations at the 2023 american society of clinical oncology (asco) annual meeting 05/25/2023
Aadi bioscience to participate in upcoming investor events 05/23/2023
Aadi bioscience announces financial results and operational update for the first quarter 2023 and provides update on precision 1 tumor agnostic trial 05/10/2023
Aadi bioscience to present multiple posters on nab-sirolimus at the 2023 american association for cancer research (aacr) annual meeting 04/14/2023
Aadi bioscience to present multiple posters at the american association for cancer research (aacr) annual meeting 2023 04/06/2023
Aadi bioscience announces financial results for the fourth quarter and full-year 2022 and provides corporate update 03/28/2023
Aadi bioscience appoints mohammad hirmand, m.d. to board of directors 03/27/2023
Aadi bioscience presents clinical data from precision 1 and ampect trials at the society of gynecological oncology (sgo) annual meeting on women's cancer 03/26/2023
Aadi bioscience announces leadership transition 03/03/2023
Aadi bioscience announces financial results for the third quarter of 2022 and provides corporate update 11/09/2022
Aadi bioscience announces improved anti-tumor activity of kras inhibitors in combination with nab-sirolimus at the 34th eortc-nci-aacr symposium 10/27/2022
Aadi bioscience announces improved anti-tumor activity of kras inhibitors in combination with nab-sirolimus at the 34th eortc-nci-aacr symposium 10/12/2022
Mirati therapeutics and aadi bioscience partner to evaluate the combination of adagrasib with nab-sirolimus in patients with advanced non-small cell lung cancer and other solid tumors with a kras[g12c] mutation 10/12/2022
Aadi bioscience announces $72.5 million private placement equity financing 09/22/2022
Aadi bioscience announces financial results for the second quarter of 2022 and provides corporate update 08/10/2022
Aadi bioscience to join russell 2000® and russell 3000® indexes 06/23/2022
Aadi bioscience appoints marcy graham senior vice president investor relations and corporate communications 05/31/2022
Aadi bioscience announces exploratory biomarker data from patients in its ampect trial and expanded access program to be presented at 2022 asco annual meeting 05/26/2022
Aadi bioscience to present at the h.c. wainwright global investment conference 05/18/2022
Update -- aadi bioscience reports first quarter 2022 financial results and provides a corporate update 05/12/2022
Aadi bioscience reports first quarter 2022 financial results and provides a corporate update 05/12/2022
Aadi bioscience announces unique permanent j-code issued for fyarro™ from centers for medicare and medicaid services 05/04/2022
Aadi bioscience to announce first quarter 2022 financial results on may 12, 2022 04/28/2022
Aadi bioscience to participate at the jefferies “biotech on the bay” summit 04/18/2022
Aadi bioscience announces data presentation on incidence of tsc1 and tsc2 alterations in advanced cancers at the annual meeting of the american association for cancer research (aacr) 04/08/2022
Aadi bioscience announces first patient dosed in its precision 1 phase 2 registrational trial of nab-sirolimus in patients with solid tumors harboring pathogenic inactivating alterations in tsc1 and tsc2 genes 03/31/2022
Aadi reports fourth quarter and full year 2021 financial results and provides business update 03/17/2022
Aadi bioscience to participate in panel discussion on tumor-agnostic development at cowen's 42nd annual health care conference 03/01/2022
Aadi bioscience announces u.s. commercial launch and availability of fyarro™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant pecoma 02/23/2022
Aadi bioscience to present at 2022 h.c. wainwright bioconnect virtual conference 01/04/2022
Aadi bioscience announces fda approval of its first product fyarro™ for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) 11/23/2021
Aadi bioscience presents two abstracts on fyarro (nab-sirolimus) at the annual meeting of the connective tissue oncology society (ctos) 11/13/2021
Aadi reports third quarter 2021 financial results and provides business update 11/10/2021
Aadi bioscience announces publication of its phase 2 registrational (ampect) trial of nab-sirolimus in patients with malignant perivascular epithelioid cell tumors in the journal of clinical oncology 10/22/2021
Aadi bioscience to participate in h.c. wainwright's 2nd annual precision oncology conference 2021 10/19/2021
Aadi bioscience appoints brendan delaney as chief operating officer 09/20/2021

More Headlines

News
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.67 per share a year ago. 08/07/2024
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES , Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers. 08/07/2024
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update Company to Host Conference Call and Webcast on August 7, 2024 LOS ANGELES , July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. 07/31/2024
3 Russell 2000 Stocks to Sell in July Before They Crash & Burn One of many stock market indexes used to measure performance, the Russell 2000 is composed of 2,000 small-cap companies that make up the bottom two-thirds of the Russell 3000 index. The reason is that the top 1,000 stocks in the Russell 3000 make up 93% of the index's market cap, so focusing on the lower 2,000 allows analysts and investors to judge the movement of the small-cap market more accurately. 07/05/2024
Aadi Bioscience to Participate in the Jefferies Healthcare Conference LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D. 05/29/2024
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES , May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mTOR inhibitors in a xenograft model. These data will be available as an abstract and published in the Journal of Clinical Oncology supplement to coincide with the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. 05/23/2024
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES , May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "I'm pleased to announce that PRECISION1 is now fully enrolled across a broad array of tumor types and our promising development plan continues to gain momentum. 05/08/2024
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. 05/01/2024
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial Data highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer LOS ANGELES , April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024. 04/09/2024
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year. 04/03/2024
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year. 03/18/2024
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers LOS ANGELES , March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status. 03/17/2024
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript 03/13/2024
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago. 03/13/2024
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track to complete enrollment by May; two-thirds interim analysis planned for Q3 2024 Phase 2 trials in Endometrial Cancer and Neuroendocrine Tumors (NETs) actively enrolling patients Conference call to be held today at 8:30 am EDT LOS ANGELES , March 13, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and highlighted recent corporate progress. "With strong execution against our commercial and development goals, 2023 was a year of progress and momentum for Aadi," said Dave Lennon, President and CEO of Aadi Bioscience. 03/13/2024
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES , March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. 03/06/2024
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 LOS ANGELES , March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. AACR poster presentation details are below: Title: " Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines " Session Title: Reversal of Drug Resistance 2 Location: Poster Section 25, Board Number 6 Abstract Number: 7196 Date/Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30 PM Presenting Author: Shihe Hou, PhD Title: "Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors" Session Title: Targeting Kinase and ERK Pathways Location: Poster Section 46, Board Number 3 Abstract Number: 6486 Date/Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM Presenting Author: Shihe Hou, PhD More information can be found on the AACR meeting website. 03/05/2024
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to 29 months in the setting of metastatic/unresectable malignant PEComa1,2 LOS ANGELES , March 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa were published in the Journal of Clinical Oncology (JCO). The manuscript, "A Phase 2 Trial of nab-Sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-term Efficacy and Safety Update," authored by Andrew J. 03/01/2024
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference LOS ANGELES , Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston. Dave Lennon, Ph.D. 02/26/2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium Real-world genomic analysis highlights unmet medical need in GU cancer patients with TSC1/2 inactivating alterations LOS ANGELES , Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA. Abstract and poster presentation details are below: Title: "Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database" Session Title: Poster Session B: Urothelial CarcinomaDate/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST Presenting Author: Gopa Iyer, MDKey Findings: In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2 TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer GU cancers with TSC1 and/or TSC2 inactivating alterations were frequently microsatellite stable and of low tumor mutational burden (TMB) The PRECISION 1 study (NCT05103358) is currently enrolling patients with solid tumors harboring TSC1 and/or TSC2 inactivating alterations Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study. 01/26/2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium - New real-world analysis highlights unmet medical need in GI cancer patients with TSC1/2 alterations- LOS ANGELES , Jan. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA. Abstract and poster presentation details are below: Title: "Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database" Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary TractDate/Time: January 19, 2024 – 12:30 – 2:00 pm Abstract: 558Presenting Author: Dustin Deming, MD Abstract Highlights: In a large real-world database of patients with advanced cancer, 1,898 (1.4%) of the 138,671 patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2 TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers Across GI malignancies, genes frequently mutated in tumors with wild-type TSC1 and TSC2 were similar to genetic mutations co-occurring in tumors with alterations in TSC1 and/or TSC2 Most TSC1 and/or TSC2 inactivating alterations in liver and pancreatic cancers occurred in the context of low TMB and MSS tumors; whereas increased TMB and MSI signatures were enriched in colorectal cancer with TSC1 and/or TSC2 alterations Limitations of this exploratory, real-world study include the timing of sampling (at initial diagnosis vs disease progression) and the absence of clinically matched outcomes data. 01/19/2024
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 12/18/2023
Why Is Aadi Bioscience (AADI) Stock Down 56% Today? Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations. 12/15/2023
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024 Study on track for completion by end 2024; final data readout expected in early 2025 Company to host conference call today at 5:00 pm EST LOS ANGELES , Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type. 12/14/2023
How Much Upside is Left in Aadi Bioscience, Inc. (AADI)? Wall Street Analysts Think 509.98% The mean of analysts' price targets for Aadi Bioscience, Inc. (AADI) points to a 510% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 11/29/2023
Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta Itri - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen Joe Catanzaro - Piper Sandler Roger Song - Jefferies Ahu Demir - Ladenburg Thalmann Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call. 11/08/2023
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago. 08/09/2023
Aadi Bioscience: High Risk/High Reward Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types. An investment analysis follows in the paragraphs below. 06/29/2023
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. 04/14/2023
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL. The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I) " Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM Session Title: Phase II and Phase III Clinical Trials in Progress Presentation Number: CT057 Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts" Date and Time: Tuesday, April 18, 2023, 1:30 - 5:00 PM Session Category: Clinical Research Excluding Trials Session Title: Poster Combination Therapies for Cancer Presentation Number: 5484 Title: " Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations " Date and Time: Wednesday, April 19, 2023, 9:00 AM - 12:30 PM Session Category: Clinical Research Excluding Trials Session Title: Late-Breaking Research: Clinical Research 3 Presentation Number: LB288 Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 \| Meetings \| AACR. 04/06/2023
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? 03/28/2023
Aadi Bioscience: Commercial Stage With Large Market In Label Expansion AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst next year. 03/06/2023
Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock? Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 01/06/2023
Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communications Neil Desai - President & Chief Executive Officer Brendan Delaney - Chief Operating Officer Loretta Itri - Chief Medical Officer Scott Giacobello - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - Cowen Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience, Inc. Third Quarter Earnings Conference Call. 11/09/2022
Aadi Bioscience: Taking mTOR Inhibition To The Next Level Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression. 09/21/2022
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO Conference Call Participants Boris Peaker - Cowen Jiale Song - Jefferies Robert Burns - H.C. Wainwright Operator Good day and thank you for standing by. 08/10/2022
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL. 05/18/2022
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call Transcript Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Development & Corporate Strategy Neil Desai - Founder, President, CEO, Secretary & Director Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO & Treasurer Conference Call Participants Boris Peaker - Cowen and Company Ahu Demir - Ladenburg Thalmann & Co. Joseph Catanzaro - Piper Sandler & Co. Jiale Song - Jefferies Operator Greetings, and welcome to the Aadi Bioscience, Inc. First Quarter 2021 Earnings Conference Call. [Operator Instructions]. 05/12/2022
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT 04/28/2022
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET. 01/04/2022
Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients. 11/25/2021
Aadi Bioscience (AADI) Stock: Why The Price Surged Today The stock price of Aadi Bioscience Inc (NASDAQ: AADI) increased by over 25% pre-market today. This is why it happened. 11/23/2021
Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa. 11/23/2021
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Misses Revenue Estimates Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -132.20% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? 11/10/2021
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Brendan Delaney to the role of Chief Operating Officer (COO). Brendan has had an established career in oncology-focused commercial leadership roles, launching multiple groundbreaking new products and building effective and cohesive commercial teams. Most recently Brendan was Chief Commercial Officer at Constellation Pharmaceuticals, which was acquired by MorphoSys AG for $1.4 billion prior to a commercial launch of pelabresib a first-in-class BETi inhibitor with blockbuster potential across multiple hematology indications. Prior to this, as Chief Commercial Officer at Immunomedics, Inc. Brendan led the launch of TRODELVY®, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer which was acquired by Gilead Sciences, Inc. for $21 billion. 09/20/2021

Unlock

AADI Ratings Summary

AADI Quant Ranking